Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 April 2025 | Story Onthatile Tikoe | Photo Kaleidoscope Studios
Thabiso Khoeli
Dr Thabiso Khoeli, Lecturer in Historical and Constructive Theology at the UFS, celebrates the completion of his PhD.

The University of the Free State (UFS) celebrated one of its own, Dr Thabiso Khoeli, a Historical and Constructive Theology Lecturer in its Faculty of Theology and Religion, when he received his PhD in Theology with specialisation in religion studies during the recently completed April graduation ceremonies. 

Dr Khoeli’s achievement not only marks a personal milestone but also advances the university’s Vision 130, a strategic initiative to position UFS as a research-led institution by its 130th anniversary in 2034. Dr Khoeli’s academic journey is one of resilience, transformation, and a profound commitment to telling African stories from an African perspective. 

 

From uncertainty to purpose

Dr Khoeli’s path into studying Theology was unplanned. As a former KovsieFootball  player, his initial academic interest was in Sports Science. However, after some admission hurdles, he found himself directed towards Theology, a field that soon captured his full attention.

“Honestly, I did not choose Theology, instead it chose me,” he shares. “… Theology whispered to me and said, ‘Do not deviate, Brother. Your calling is here.” Despite initial scepticism, his first semester revealed the intellectual and spiritual depth of the discipline, compelling him to pursue it with passion.

 

A research focus on African voices

His doctoral research, titled ‘Exploring the Zion Christian Church’s Teachings and Qualities in Comparison with Zion Churches’, examines the theological, historical, and cultural distinctiveness of the Zion Christian Church (ZCC), one of the largest and most influential religious movements in Africa. Motivated by a desire to decolonise theology and challenge externally imposed narratives, Dr Khoeli engaged directly with primary sources, including archival materials and interviews with Church elders.

“Africans must now write their own stories and never rely on the findings presented by others,” he says. His work not only fills critical gaps in theological scholarship but also reflects the UFS’s vision of becoming a centre of thought leadership on the African continent.

 

Research shaping teaching

As a Lecturer in Historical and Constructive Theology, Dr Khoeli’s research directly informs his methods of teaching. He approaches the classroom with a decolonised, historically grounded perspective that helps his students engage with both their spiritual heritage and contemporary realities critically.

“My research enabled me to analyse documents and align them to my objective,” he explains. “That is the strategy I use to collect the relevant reading materials to prepare for the students.” His teaching method fosters independent thinking and encourages students to become scholars who are both academically rigorous and socially conscious.

 

Overcoming challenges through community and conviction

Gaining access to the ZCC’s historical documents was a major challenge. The Church’s deep-rooted secrecy required careful relationship-building and persistent effort. But Dr Khoeli remained undeterred. “I intended to leave no stone unturned,” he says. Through perseverance, mentorship, and faith, he accessed essential material for his literature-based study.

He also credits colleagues at the Faculty of Theology and Religion for their belief in his potential at a time when few others would give him a chance. “It feels great,” he reflects. “I don’t have enough words to explain how overwhelming it feels to prove to yourself that you are the greatest.”

 

A vision beyond the doctorate

With his PhD now complete, Dr Khoeli is setting his sights on further research projects that contribute to the reconstruction of African religious history and knowledge systems. He sees his work as part of a larger mission to revive indigenous spirituality and cultural identity in the face of modern erasure.

“Modernity is converting us to be a nation without roots,” he cautions. His aim is to produce scholarship that restores heritage while also responding to the physical and spiritual needs of African communities, one of the fundamental goals of the UFS’s Vision 130.

 

Inspiring the next generation

To current and future UFS students, especially those considering postgraduate study, Dr Khoeli offers this message, with his own story as proof: “Believe in your purpose, even when the path seems uncertain… There is greatness in you.” 

Through his academic excellence, teaching innovation, and dedication to African-centred research, Dr Khoeli exemplifies the values of the UFS’s Vision 130. His journey reflects a university that is not only committed to high-impact research but also to empowering scholars who bring change, both in the academic world and beyond.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept